Gabriel Mannis, MD



Cancer Immunotherapy Clinic
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Phone for Existing Patients: (415) 353-2421
Phone for New Patients: (415) 353-2051

Hours: Monday to Friday, 8 a.m. – 5 p.m.

Hematology and Blood and Marrow Transplant
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
Fax: (415) 353-2467

Hours: Monday to Friday
8 a.m. – 5 p.m

Board Certification

Hematology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine

Academic Title

Assistant Professor

More about Gabriel Mannis


University of California Davis School of Medicine 2008


UCSF Medical Center 2011


UCSF Medical Center 2014

Selected Research and Publications

  1. Foley N, Van Ziffle J, Yu J, Qi Z, Grenert JP, Yeh I, Bastian B, Kogan S, Mannis GN. Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation? Cancer Genet. 2017 Oct; 216-217:74-78.
  2. Gupta NK, Wang CC, Mannis GN, Yu JJ, Rubenstein JL. Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy. Leuk Lymphoma. 2017 Nov; 58(11):2748-2751.
  3. Eckhert EE, Schoenbeck KL, Galligan D, McNey LM, Hwang J, Mannis GN. Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant. Bone Marrow Transplant. 2017 Jun; 52(6):929-931.
  4. Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017 Jan; 19(1):99-108.
  5. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Nov; 22(11):1974-1982.
  6. Mannis TE, Mannis GN, Waterhouse EG, Aldave AJ, Rose-Nussbaumer J. Paraproteinemic keratopathy as the presenting sign of hematologic malignancy. Am J Hematol. 2016 Sep; 91(9):961-2.
  7. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Jun; 22(6):1030-1036.
  8. Mannis GN, McNey LM, Gupta NK, Gross DM. The transfusion tether: Bridging the gap between end-stage hematologic malignancies and optimal end-of-life care. Am J Hematol. 2016 Jun; 91(4):364-5.
  9. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 Jul; 57(7):1560-6.
  10. Byrne M, Mannis GN, Nair J, Andreadis C. Inferior vena cava filter thrombosis. Clin Case Rep. 2016 Feb; 4(2):162-4.
  11. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.
  12. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4.
  13. Mannis G, Wu D, Dea T, Mauro T, Hsu G. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia. Am J Hematol. 2015 Feb; 90(2):179.
  14. Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013 Oct 03; 122(14):2318-30.
  15. Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS. Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. JAMA Intern Med. 2013 Jan 28; 173(2):96-103.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.